<unk> , sold under the brand Targretin, is an antineoplastic (anti-cancer) agent approved by the U.S. Food and Drug Administration (FDA) (December 1999) and the European Medicines Agency (EMA) (March 2001) for use as a treatment for cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid.
Bexarotene
Trifarotene
Tazarotene
Sulfalene
Retinol
Metenolone enanthate
Trenbolone enanthate
Stenbolone acetate